GlassScriptPhysician profile
William T Derosa
NPI 1902894991
$14,942.20
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $118 · 2021: $102 · 2022: $41.44 · 2023: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13,434.66 | 2019-2023 | |
| Janssen Research & Development, LLC | $461.17 | 2019 | |
| Daiichi Sankyo INC. | $165.09 | 2023 | |
| Novartis Pharmaceuticals Corporation | $131.27 | 2019-2023 | |
| Celgene Corporation | $126.64 | 2022-2023 | |
| Genmab U.S., INC. | $114.51 | 2023 | Epkinly |
| Incyte Corporation | $99.00 | 2019 | |
| Seagen INC. | $55.90 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $53.58 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $38.42 | 2021 | |
| Sirtex Medical INC | $35.87 | 2019-2020 | |
| Eisai INC. | $29.74 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.11 | 2019 | |
| Merck Sharp & Dohme LLC | $27.61 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26.62 | 2019-2021 | |
| Pfizer INC. | $26.13 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $15.00 | 2020 | |
| Genzyme Corporation | $14.58 | 2020 | |
| Emd Serono, INC. | $14.42 | 2019 | |
| Janssen Biotech, INC. | $13.50 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Derosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.